Glaxo to take full control of Cellzome
Drugs giant GlaxoSmithKline is to take full control of Cellzome, a company specialising in the study of protein structures and functions.
Drugs giant GlaxoSmithKline is to take full control of Cellzome, a company specialising in the study of protein structures and functions.
Glaxo, which currently owns just under one fifth of Cambridge-based Cellzome, is paying £61m in cash to buy up the rest of the company, which will become part of Glaxo's research and development (R&D) organisation.
Cellzome's proteomics technologies can be used throughout the drug discovery process from screening to selectivity profiling of compounds in different cells and also in patient samples.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The technologies that Cellzome has developed differ from other traditional methods used in early drug discovery by assessing drug interactions with target proteins in a setting which more closely represents that found in a whole biological system. This allows scientists the opportunity to observe how candidate drugs affect both intended and non-desired targets in a close-to-physiological environment and may pinpoint potential safety issues earlier in the process.
Glaxo and Cellzome have two active early stage research collaborations using these discovery capabilities within the immune-inflammation therapy area.
Simultaneous with the acquisition, Cellzome shareholders, including Glaxo, intend to create a spin-off company, which would hold the rights to certain of Cellzome's assets and activities that Glaxo does not want as part of its drugs development pipeline.
JH
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.
-
Inheritance tax home loan scheme beats HMRC but lawyers warn of the risks
Schemes widely sold to the middle classes in the early 2000s to avoid inheritance tax are now finding their way to the courts as the tax office disputes their legality
-
How high earners could boost their pension by thousands and cut childcare costs
Salary sacrifice could boost your pension by thousands, while also helping you save on childcare costs. We delve into the numbers.